Avandia panel member may be investigated for possible conflicts of interest.
作者信息
Tanne Janice Hopkins
出版信息
BMJ. 2010 Aug 3;341:c4083. doi: 10.1136/bmj.c4083.
PMID:20682621
Abstract
摘要
相似文献
1
Avandia panel member may be investigated for possible conflicts of interest.
BMJ. 2010 Aug 3;341:c4083. doi: 10.1136/bmj.c4083.
2
Major US consumer group asks FDA to ban drug for diabetes.
BMJ. 2008 Nov 5;337:a2401. doi: 10.1136/bmj.a2401.
3
Commentary: What can we learn from the continuing regulatory focus on the thiazolidinediones?
BMJ. 2010 Sep 6;341:c4812. doi: 10.1136/bmj.c4812.
4
Rosiglitazone: what went wrong?
BMJ. 2010 Sep 6;341:c4848. doi: 10.1136/bmj.c4848.
5
Licensing drugs for diabetes.
BMJ. 2010 Sep 6;341:c4805. doi: 10.1136/bmj.c4805.
6
Lessons from the Avandia controversy: a new paradigm for the development of drugs to treat type 2 diabetes.
Diabetes Care. 2007 Dec;30(12):3141-4. doi: 10.2337/dc07-1908.
7
FDA places greater restrictions on access to rosiglitazone.
BMJ. 2010 Sep 24;341:c5287. doi: 10.1136/bmj.c5287.
8
FDA committees say keep rosiglitazone available but increase warnings.
BMJ. 2007 Aug 4;335(7613):223. doi: 10.1136/bmj.39294.417442.DB.
9
NIH opens conflict-of-interest investigation.
Nat Med. 1999 Feb;5(2):129-30. doi: 10.1038/5479.
10
Anticipated US approval for rosiglitazone and pioglitazone.
Diabetes Obes Metab. 1999 May;1(3):181-2.
Zotero 插件